CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Carboplatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03188432
NCT03188432Phase 2Completed

A Phase II Trial Comparing Quality of Life After HIPEC in Patients With Stage IIIC and IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

Wake Forest University Health Sciences·interventional·Posted Jun 15, 2017·Updated Oct 21, 2025

In Brief

A Phase 2 clinical trial evaluating Carboplatin, Quality-of-Life Assessment, and 2 other interventions for Stage IIIC Fallopian Tube Cancer and 5 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may help the drugs get into the cancer cells better, minimize the toxicity of the drugs on normal cells, and help to kill any cancer cells left over after surgery.

Study Details

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 15, 2017
Enrollment StartJan 2, 2019
Primary CompletionJan 31, 2024
Study CompletionFeb 8, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.0 years ago

Interventions

Carboplatindrug

Given IV and IP

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies

Cytoreductive Surgeryprocedure

Undergo CRS